Baker Bros. Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Baker Bros. Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,810,248	Closed	-$337M	–	90
2023 Q3	$337M	Hold	3,810,248	–	–	1.94%	5
2023 Q2	$330M	Hold	3,810,248	–	–	1.91%	6
2023 Q1	$371M	Sell	3,810,248 -3,810,246	-50%	-$395M	2.02%	6
2022 Q4	$789M	Hold	7,620,494	–	–	4.74%	4
2022 Q3	$646M	Hold	7,620,494	–	–	4.23%	5
2022 Q2	$632M	Hold	7,620,494	–	–	3.58%	4
2022 Q1	$588M	Hold	7,620,494	–	–	3.38%	5
2021 Q4	$673M	Hold	7,620,494	–	–	3.28%	6
2021 Q3	$589M	Buy	7,620,494 +31,200	+0.4%	+$2.46M	2.59%	7
2021 Q2	$633M	Hold	7,589,294	–	–	2.78%	6
2021 Q1	$573M	Hold	7,589,294	–	–	2.48%	8
2020 Q4	$666M	Hold	7,589,294	–	–	2.51%	8
2020 Q3	$577M	Hold	7,589,294	–	–	2.31%	7
2020 Q2	$936M	Hold	7,589,294	–	–	4.13%	6
2020 Q1	$641M	Hold	7,589,294	–	–	3.95%	6
2019 Q4	$642M	Hold	7,589,294	–	–	3.41%	8
2019 Q3	$512M	Hold	7,589,294	–	–	3.48%	8
2019 Q2	$650M	Hold	7,589,294	–	–	4.42%	7
2019 Q1	$674M	Hold	7,589,294	–	–	4.32%	8
2018 Q4	$646M	Buy	7,589,294 +6,210	+0.1%	+$591K	5.29%	6
2018 Q3	$735M	Hold	7,583,084	–	–	4.84%	6
2018 Q2	$714M	Hold	7,583,084	–	–	5.37%	5
2018 Q1	$615M	Hold	7,583,084	–	–	5.21%	5
2017 Q4	$676M	Buy	7,583,084 +1,677,411	+28%	+$146M	5.86%	5
2017 Q3	$550M	Hold	5,905,673	–	–	4.46%	5
2017 Q2	$536M	Buy	5,905,673 +1,099,190	+23%	+$100M	4.69%	5
2017 Q1	$422M	Hold	4,806,483	–	–	3.45%	6
2016 Q4	$398M	Hold	4,806,483	–	–	3.9%	8
2016 Q3	$445M	Hold	4,806,483	–	–	4.04%	8
2016 Q2	$374M	Hold	4,806,483	–	–	3.92%	8
2016 Q1	$396M	Buy	4,806,483 +691,400	+17%	+$56.3M	4.18%	8
2015 Q4	$431M	Buy	4,115,083 +38,730	+1%	+$4.04M	3.57%	10
2015 Q3	$429M	Sell	4,076,353 -18,894	-0.5%	-$2.52M	3.97%	9
2015 Q2	$560M	Sell	4,095,247 -105,209	-3%	-$13M	4.91%	7
2015 Q1	$523M	Buy	4,200,456 +486,506	+13%	+$51.5M	4.35%	7
2014 Q4	$336M	Buy	3,713,950 +1,343,486	+57%	+$112M	3.43%	12
2014 Q3	$171M	Buy	2,370,464 +462,234	+24%	+$30.4M	2.15%	12
2014 Q2	$119M	Buy	1,908,230 +25,000	+1%	+$1.51M	1.45%	14
2014 Q1	$128M	Sell	1,883,230 -58,074	-3%	-$4.28M	1.63%	13
2013 Q4	$137M	Buy	1,941,304 +1,157,993	+148%	+$78.6M	1.92%	12
2013 Q3	$56.5M	Hold	783,311	–	–	0.8%	20
2013 Q2	$43.7M	Buy	+783,311	New	+$48.8M	0.86%	20

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Baker Bros. Advisors's BMRN Position: Q4 2023 in Review

Baker Bros. Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 3,810,248 shares — an estimated $337M sold.

Baker Bros. Advisors first reported a position in BMRN in Q2 2013 and held it in 42 quarters. The position peaked at $936M in Q2 2020. 548 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Baker Bros. Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Baker Bros. Advisors sold 3,810,248 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $337M.
Baker Bros. Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 42 quarters.
Baker Bros. Advisors's BioMarin Pharmaceuticals position peaked at $936M in Q2 2020.
548 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.